AstraZeneca: PT027 promising in asthma
(CercleFinance.com) - AstraZeneca has announced that a phase III trial of PT027 (albuterol/budesonide) demonstrated a statistically significant reduction in the risk of severe exacerbations in patients with moderate-to- severe asthma.
For example, compared to albuterol, PT027 at a dose of 180 mcg albuterol/160 mcg budesonide reduced the risk of severe exacerbation by 27% in adults and adolescents.
This inhaled rescue medication is being developed by AstraZeneca and Avillion.
The results of these phase III trials confirm the clinical benefit of PT027 (...) which has the potential to become a first-in-class treatment to prevent asthma attacks beyond current maintenance therapies, AstraZeneca said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.